Vulvovaginal Candidiasis Treatment Market Report 2026

The vulvovaginal candidiasis treatment market size has grown strongly in recent years. It will grow from $1.18 billion in 2025 to $1.24 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to availability of azole antifungal medications, expansion of retail pharmacy access, increased diagnosis of fungal infections, improved formulation of topical treatments, widespread clinical treatment guidelines.

The vulvovaginal candidiasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.51 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to growing demand for novel antifungal agents, rising focus on resistance management, expansion of personalized treatment approaches, increasing adoption of telehealth consultations, advancements in drug delivery technologies. Major trends in the forecast period include increasing adoption of targeted antifungal therapies, rising use of combination treatment regimens, growing focus on recurrence prevention strategies, expansion of over-the-counter treatment options, enhanced patient awareness and education.

The increasing awareness of vaginal disorders is expected to drive the growth of the vulvovaginal candidiasis (VVC) treatment market in the coming years. Vaginal disorders are conditions that affect the vagina, including infections, inflammation, irritation, or abnormal discharge. Growing awareness of these disorders is fueled by enhanced education, improved access to healthcare, and an increasing focus on women’s health and well-being. VVC treatments help patients by alleviating symptoms such as itching, irritation, and abnormal discharge, restoring the natural vaginal microbiome, preventing recurrent infections, and improving overall vaginal health and comfort. For example, in September 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, approximately 209,253 syphilis cases were reported in 2023, reflecting a 1% increase from 207,269 cases in 2022. Therefore, the rising awareness of vaginal disorders is supporting the growth of the vulvovaginal candidiasis treatment market.

Key companies operating in the VVC treatment market are focusing on innovative solutions, such as selective oral azole antifungals, to improve treatment efficacy, reduce recurrence, and enhance patient tolerability. Selective oral azoles are antifungal medications that specifically inhibit fungal enzymes like CYP51, minimizing off-target effects and adverse reactions compared with traditional broad-spectrum azoles. For instance, in February 2024, Mycovia Pharmaceuticals, Inc., a US-based biopharmaceutical company, in partnership with Jiangsu Hengrui Pharmaceuticals Co., Ltd., launched VIVJOA (oteseconazole) capsules in China for severe vulvovaginal candidiasis. VIVJOA is administered as a two-day oral regimen, offering superior cure rates compared with fluconazole while providing a shorter, targeted course of therapy. This product represents a significant advancement in VVC management by delivering an effective, patient-friendly treatment option for difficult-to-treat cases.

In February 2024, Mycovia Pharmaceuticals, Inc. collaborated with Jiangsu Hengrui Pharmaceuticals Co., Ltd. to launch VIVJOA capsules in China for the treatment of severe VVC. Through this partnership, both companies aim to provide an effective therapy for severe vulvovaginal candidiasis, address unmet medical needs, and expand treatment options for long-term management of fungal infections. Jiangsu Hengrui Pharmaceuticals Co., Ltd., based in China, specializes in treatments for vulvovaginal candidiasis.

Major companies operating in the vulvovaginal candidiasis treatment market are Pfizer Inc., Bayer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences, Novartis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Taro Pharmaceuticals Industries Ltd., Accord Healthcare Ltd., Incepta Pharmaceuticals Ltd., Cadila Pharmaceuticals, Astellas Pharma Inc., Mycovia Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Scynexis Inc., Grupo Ferrer Internacional SA, Sanofi SA, Bristol‑Myers Squibb Company, Perrigo Company plc, Lupin Limited, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the vulvovaginal candidiasis treatment market in 2025. The regions covered in the vulvovaginal candidiasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vulvovaginal candidiasis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the vulvovaginal candidiasis treatment market by increasing costs of imported active pharmaceutical ingredients, antifungal compounds, packaging materials, and manufacturing equipment. Retail and hospital pharmacies in North America and Europe are most affected due to reliance on global drug supply chains, while Asia-Pacific faces pricing pressure on export-oriented pharmaceutical production. These tariffs can increase medication prices and affect affordability. However, they are also driving local API production, domestic drug manufacturing, and supply chain diversification to ensure long-term treatment availability.

The vulvovaginal candidiasis treatment market research report is one of a series of new reports that provides vulvovaginal candidiasis treatment market statistics, including vulvovaginal candidiasis treatment industry global market size, regional shares, competitors with a vulvovaginal candidiasis treatment market share, detailed vulvovaginal candidiasis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the vulvovaginal candidiasis treatment industry. This vulvovaginal candidiasis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vulvovaginal candidiasis treatment refers to the medical management of a common fungal infection caused by Candida species, which affects the vaginal area. The treatment is intended to alleviate symptoms such as itching, burning, and abnormal discharge. The primary goal of these treatments is to relieve discomfort, restore vaginal balance, and prevent recurrence of the infection.

The primary drugs used for vulvovaginal candidiasis include clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others. Clotrimazole, an antifungal medication, is commonly used to treat vulvovaginal candidiasis. It can be administered orally, intravenously, or topically and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The vulvovaginal candidiasis treatment market consists of sales of antifungal creams, oral antifungal capsules, suppositories, vaginal gels, pessaries, and non-azole medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.